<DOC>
	<DOCNO>NCT00113516</DOCNO>
	<brief_summary>The purpose study find SU011248 ( sunitinib ) provide additional benefit give treatment two chemotherapy drug carboplatin paclitaxel also sunitinib safe patient locally advance metastatic Non Small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven NSCLC Stage IIIB ( locally advance malignant effusion ) Stage IV disease No prior therapy NSCLC Evidence unidimensionally measurable disease Previous treatment systemic chemotherapy lung cancer History know brain metastasis NCI CTCAE Grade 3 hemorrhage within 4 week start study treatment Evidence hemoptysis within 4 week start study treatment Serious acute chronic illness recent history significant cardiac abnormality Previous treatment antiangiogenesis agent include thalidomide , inhibitor EGFR PDGFR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Lung Neoplasms</keyword>
</DOC>